Stereotaxis EBITDA 2010-2025 | STXS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Stereotaxis ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Stereotaxis ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$184.5B
Intuitive Surgical (ISRG)	$170B
IDEXX Laboratories (IDXX)	$51.3B
Edwards Lifesciences (EW)	$47.7B
Alcon (ALC)	$40.2B
IQVIA Holdings (IQV)	$31.9B
DexCom (DXCM)	$29.9B
Mettler-Toledo (MTD)	$26.5B
STERIS (STE)	$24.5B
Waters (WAT)	$17.6B
SONOVA HOLDING (SONVY)	$16.9B
Hologic (HOLX)	$14.8B
Penumbra (PEN)	$10.4B
Globus Medical (GMED)	$8.4B
Sysmex ADR (SSMXY)	$8.1B
Masimo (MASI)	$7.8B
Teleflex (TFX)	$5.6B
Glaukos (GKOS)	$5.4B
TransMedics (TMDX)	$3.9B
Integer Holdings (ITGR)	$3.8B
LivaNova (LIVN)	$3.1B
Alphatec Holdings (ATEC)	$2.4B
Veracyte (VCYT)	$2.3B
PROCEPT BioRobotics (PRCT)	$2.3B
Artivion (AORT)	$2.1B
Nihon Kohden (NHNKY)	$1.9B
Elekta AB (EKTAY)	$1.9B
Integra LifeSciences Holdings (IART)	$1.1B
Pulse Biosciences (PLSE)	$1.1B
OPKO Health (OPK)	$1.1B